nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—muscle cancer—uterine cancer	0.208	0.527	CtDrD
Methotrexate—germ cell cancer—uterine cancer	0.187	0.473	CtDrD
Methotrexate—MTHFR—uterine cancer	0.178	1	CbGaD
Methotrexate—ABCC10—Etoposide—uterine cancer	0.0308	0.125	CbGbCtD
Methotrexate—ABCC1—Progesterone—uterine cancer	0.0266	0.108	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—uterine cancer	0.0211	0.0857	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—uterine cancer	0.021	0.0855	CbGbCtD
Methotrexate—ABCC3—Etoposide—uterine cancer	0.0194	0.0788	CbGbCtD
Methotrexate—ABCC1—Epirubicin—uterine cancer	0.0153	0.0621	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—uterine cancer	0.0141	0.0574	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—uterine cancer	0.0132	0.0537	CbGbCtD
Methotrexate—ABCC1—Etoposide—uterine cancer	0.0119	0.0484	CbGbCtD
Methotrexate—ABCC2—Carboplatin—uterine cancer	0.0105	0.0426	CbGbCtD
Methotrexate—ABCG2—Carboplatin—uterine cancer	0.00948	0.0386	CbGbCtD
Methotrexate—ABCC2—Etoposide—uterine cancer	0.00881	0.0358	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—uterine cancer	0.00812	0.033	CbGbCtD
Methotrexate—ABCG2—Etoposide—uterine cancer	0.00796	0.0324	CbGbCtD
Methotrexate—ABCB1—Progesterone—uterine cancer	0.00642	0.0261	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—uterine cancer	0.00601	0.0244	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—uterine cancer	0.00543	0.0221	CbGbCtD
Methotrexate—ABCB1—Dactinomycin—uterine cancer	0.00509	0.0207	CbGbCtD
Methotrexate—FOLR1—oviduct—uterine cancer	0.00307	0.0612	CbGeAlD
Methotrexate—ABCB1—Etoposide—uterine cancer	0.00287	0.0117	CbGbCtD
Methotrexate—ABCB1—Doxorubicin—uterine cancer	0.00196	0.00796	CbGbCtD
Methotrexate—FOLR1—exocrine gland—uterine cancer	0.00177	0.0353	CbGeAlD
Methotrexate—MTHFR—artery—uterine cancer	0.000853	0.017	CbGeAlD
Methotrexate—FOLR1—epithelium—uterine cancer	0.000771	0.0154	CbGeAlD
Methotrexate—FOLR1—uterine cervix—uterine cancer	0.000764	0.0152	CbGeAlD
Methotrexate—FOLR1—decidua—uterine cancer	0.000728	0.0145	CbGeAlD
Methotrexate—FOLR1—renal system—uterine cancer	0.000715	0.0143	CbGeAlD
Methotrexate—FOLR1—endometrium—uterine cancer	0.000691	0.0138	CbGeAlD
Methotrexate—GGH—myometrium—uterine cancer	0.000652	0.013	CbGeAlD
Methotrexate—FOLR1—uterus—uterine cancer	0.000637	0.0127	CbGeAlD
Methotrexate—FPGS—myometrium—uterine cancer	0.000574	0.0114	CbGeAlD
Methotrexate—FOLR1—female reproductive system—uterine cancer	0.000572	0.0114	CbGeAlD
Methotrexate—ATIC—Levonorgestrel—Progesterone—uterine cancer	0.000567	0.495	CbGdCrCtD
Methotrexate—Folic Acid—MTHFR—uterine cancer	0.000555	0.5	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—uterine cancer	0.000555	0.5	CrCbGaD
Methotrexate—ABCC11—female reproductive system—uterine cancer	0.000549	0.0109	CbGeAlD
Methotrexate—FOLR1—female gonad—uterine cancer	0.000521	0.0104	CbGeAlD
Methotrexate—GGH—uterine cervix—uterine cancer	0.000508	0.0101	CbGeAlD
Methotrexate—SLC19A1—female reproductive system—uterine cancer	0.000502	0.01	CbGeAlD
Methotrexate—ABCC11—female gonad—uterine cancer	0.000499	0.00996	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—uterine cancer	0.000493	0.00984	CbGeAlD
Methotrexate—SLC46A1—decidua—uterine cancer	0.000492	0.00981	CbGeAlD
Methotrexate—GGH—decidua—uterine cancer	0.000484	0.00965	CbGeAlD
Methotrexate—GGH—renal system—uterine cancer	0.000475	0.00948	CbGeAlD
Methotrexate—GGH—endometrium—uterine cancer	0.000459	0.00916	CbGeAlD
Methotrexate—GGH—mammalian vulva—uterine cancer	0.000444	0.00886	CbGeAlD
Methotrexate—ATIC—epithelium—uterine cancer	0.000435	0.00869	CbGeAlD
Methotrexate—FPGS—decidua—uterine cancer	0.000425	0.00848	CbGeAlD
Methotrexate—GGH—uterus—uterine cancer	0.000423	0.00844	CbGeAlD
Methotrexate—SLCO4C1—renal system—uterine cancer	0.000421	0.0084	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—uterine cancer	0.00042	0.00837	CbGeAlD
Methotrexate—SLCO4C1—endometrium—uterine cancer	0.000407	0.00812	CbGeAlD
Methotrexate—SLCO3A1—myometrium—uterine cancer	0.000406	0.00809	CbGeAlD
Methotrexate—ATIC—renal system—uterine cancer	0.000404	0.00806	CbGeAlD
Methotrexate—FPGS—endometrium—uterine cancer	0.000404	0.00805	CbGeAlD
Methotrexate—SLCO4C1—mammalian vulva—uterine cancer	0.000394	0.00786	CbGeAlD
Methotrexate—FPGS—mammalian vulva—uterine cancer	0.000391	0.00779	CbGeAlD
Methotrexate—GGH—female reproductive system—uterine cancer	0.00038	0.00759	CbGeAlD
Methotrexate—DHFR—myometrium—uterine cancer	0.000373	0.00743	CbGeAlD
Methotrexate—ATIC—uterus—uterine cancer	0.00036	0.00718	CbGeAlD
Methotrexate—PGD—myometrium—uterine cancer	0.000358	0.00714	CbGeAlD
Methotrexate—SLC46A1—female gonad—uterine cancer	0.000352	0.00702	CbGeAlD
Methotrexate—GGH—female gonad—uterine cancer	0.000346	0.00691	CbGeAlD
Methotrexate—GGH—vagina—uterine cancer	0.000344	0.00686	CbGeAlD
Methotrexate—SLCO1C1—renal system—uterine cancer	0.000336	0.0067	CbGeAlD
Methotrexate—FPGS—female reproductive system—uterine cancer	0.000334	0.00667	CbGeAlD
Methotrexate—SLC22A11—renal system—uterine cancer	0.000326	0.00651	CbGeAlD
Methotrexate—ATIC—female reproductive system—uterine cancer	0.000323	0.00645	CbGeAlD
Methotrexate—SLC22A7—renal system—uterine cancer	0.000318	0.00635	CbGeAlD
Methotrexate—SLCO3A1—uterine cervix—uterine cancer	0.000316	0.0063	CbGeAlD
Methotrexate—AOX1—myometrium—uterine cancer	0.000316	0.00629	CbGeAlD
Methotrexate—TYMS—Podofilox—Etoposide—uterine cancer	0.000307	0.268	CbGdCrCtD
Methotrexate—ABCC10—myometrium—uterine cancer	0.000307	0.00613	CbGeAlD
Methotrexate—SLCO4C1—vagina—uterine cancer	0.000305	0.00609	CbGeAlD
Methotrexate—FPGS—female gonad—uterine cancer	0.000304	0.00607	CbGeAlD
Methotrexate—FPGS—vagina—uterine cancer	0.000302	0.00603	CbGeAlD
Methotrexate—SLCO1B3—vagina—uterine cancer	0.000297	0.00592	CbGeAlD
Methotrexate—SLCO3A1—renal system—uterine cancer	0.000295	0.00589	CbGeAlD
Methotrexate—ATIC—female gonad—uterine cancer	0.000294	0.00587	CbGeAlD
Methotrexate—SLC19A1—lymph node—uterine cancer	0.000294	0.00586	CbGeAlD
Methotrexate—TYMS—uterine cervix—uterine cancer	0.000293	0.00584	CbGeAlD
Methotrexate—DHFR—uterine cervix—uterine cancer	0.00029	0.00578	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—uterine cancer	0.000285	0.00568	CbGeAlD
Methotrexate—PGD—uterine cervix—uterine cancer	0.000279	0.00556	CbGeAlD
Methotrexate—SLCO3A1—mammalian vulva—uterine cancer	0.000276	0.00551	CbGeAlD
Methotrexate—DHFR—decidua—uterine cancer	0.000276	0.00551	CbGeAlD
Methotrexate—DHFR—renal system—uterine cancer	0.000271	0.00541	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—uterine cancer	0.000271	0.0054	CbGeAlD
Methotrexate—PGD—decidua—uterine cancer	0.000266	0.0053	CbGeAlD
Methotrexate—TYMS—endometrium—uterine cancer	0.000265	0.00528	CbGeAlD
Methotrexate—SLC16A1—epithelium—uterine cancer	0.000262	0.00523	CbGeAlD
Methotrexate—DHFR—endometrium—uterine cancer	0.000262	0.00523	CbGeAlD
Methotrexate—SLC22A11—female reproductive system—uterine cancer	0.000261	0.00521	CbGeAlD
Methotrexate—PGD—renal system—uterine cancer	0.000261	0.0052	CbGeAlD
Methotrexate—TYMS—mammalian vulva—uterine cancer	0.000256	0.00511	CbGeAlD
Methotrexate—DHFR—mammalian vulva—uterine cancer	0.000254	0.00506	CbGeAlD
Methotrexate—PGD—endometrium—uterine cancer	0.000252	0.00503	CbGeAlD
Methotrexate—SLC16A1—decidua—uterine cancer	0.000248	0.00494	CbGeAlD
Methotrexate—AOX1—uterine cervix—uterine cancer	0.000246	0.0049	CbGeAlD
Methotrexate—PGD—mammalian vulva—uterine cancer	0.000244	0.00486	CbGeAlD
Methotrexate—SLC16A1—renal system—uterine cancer	0.000243	0.00486	CbGeAlD
Methotrexate—DHFR—uterus—uterine cancer	0.000242	0.00482	CbGeAlD
Methotrexate—MTHFR—female reproductive system—uterine cancer	0.00024	0.0048	CbGeAlD
Methotrexate—ABCC10—uterine cervix—uterine cancer	0.000239	0.00477	CbGeAlD
Methotrexate—SLCO1B1—renal system—uterine cancer	0.000237	0.00472	CbGeAlD
Methotrexate—SLCO3A1—female reproductive system—uterine cancer	0.000237	0.00472	CbGeAlD
Methotrexate—SLC16A1—endometrium—uterine cancer	0.000235	0.00469	CbGeAlD
Methotrexate—AOX1—decidua—uterine cancer	0.000234	0.00467	CbGeAlD
Methotrexate—PGD—uterus—uterine cancer	0.000232	0.00463	CbGeAlD
Methotrexate—AOX1—renal system—uterine cancer	0.00023	0.00458	CbGeAlD
Methotrexate—ABCC3—decidua—uterine cancer	0.000229	0.00456	CbGeAlD
Methotrexate—ABCC10—decidua—uterine cancer	0.000228	0.00454	CbGeAlD
Methotrexate—SLC46A1—lymph node—uterine cancer	0.000226	0.00451	CbGeAlD
Methotrexate—ABCC3—renal system—uterine cancer	0.000225	0.00448	CbGeAlD
Methotrexate—ABCC10—renal system—uterine cancer	0.000224	0.00446	CbGeAlD
Methotrexate—GGH—lymph node—uterine cancer	0.000223	0.00444	CbGeAlD
Methotrexate—AOX1—endometrium—uterine cancer	0.000222	0.00443	CbGeAlD
Methotrexate—TYMS—female reproductive system—uterine cancer	0.000219	0.00438	CbGeAlD
Methotrexate—MTHFR—female gonad—uterine cancer	0.000219	0.00436	CbGeAlD
Methotrexate—ABCC1—myometrium—uterine cancer	0.000217	0.00433	CbGeAlD
Methotrexate—DHFR—female reproductive system—uterine cancer	0.000217	0.00433	CbGeAlD
Methotrexate—SLC16A1—uterus—uterine cancer	0.000217	0.00433	CbGeAlD
Methotrexate—ABCC10—endometrium—uterine cancer	0.000216	0.00431	CbGeAlD
Methotrexate—SLCO3A1—female gonad—uterine cancer	0.000215	0.00429	CbGeAlD
Methotrexate—AOX1—mammalian vulva—uterine cancer	0.000215	0.00428	CbGeAlD
Methotrexate—SLCO3A1—vagina—uterine cancer	0.000214	0.00427	CbGeAlD
Methotrexate—ABCC10—mammalian vulva—uterine cancer	0.000209	0.00417	CbGeAlD
Methotrexate—PGD—female reproductive system—uterine cancer	0.000209	0.00417	CbGeAlD
Methotrexate—AOX1—uterus—uterine cancer	0.000205	0.00408	CbGeAlD
Methotrexate—TYMS—female gonad—uterine cancer	0.0002	0.00398	CbGeAlD
Methotrexate—ABCC10—uterus—uterine cancer	0.000199	0.00397	CbGeAlD
Methotrexate—TYMS—vagina—uterine cancer	0.000198	0.00396	CbGeAlD
Methotrexate—DHFR—female gonad—uterine cancer	0.000198	0.00394	CbGeAlD
Methotrexate—DHFR—vagina—uterine cancer	0.000196	0.00392	CbGeAlD
Methotrexate—FPGS—lymph node—uterine cancer	0.000196	0.0039	CbGeAlD
Methotrexate—SLC16A1—female reproductive system—uterine cancer	0.000195	0.00389	CbGeAlD
Methotrexate—SLCO1A2—renal system—uterine cancer	0.000193	0.00384	CbGeAlD
Methotrexate—PGD—female gonad—uterine cancer	0.00019	0.00379	CbGeAlD
Methotrexate—SLCO1B1—female reproductive system—uterine cancer	0.00019	0.00378	CbGeAlD
Methotrexate—ATIC—lymph node—uterine cancer	0.000189	0.00377	CbGeAlD
Methotrexate—PGD—vagina—uterine cancer	0.000189	0.00377	CbGeAlD
Methotrexate—ABCC4—renal system—uterine cancer	0.000185	0.0037	CbGeAlD
Methotrexate—SLC22A8—renal system—uterine cancer	0.000184	0.00367	CbGeAlD
Methotrexate—AOX1—female reproductive system—uterine cancer	0.000184	0.00367	CbGeAlD
Methotrexate—ABCC3—female reproductive system—uterine cancer	0.00018	0.00359	CbGeAlD
Methotrexate—ABCG2—myometrium—uterine cancer	0.00018	0.00359	CbGeAlD
Methotrexate—ABCC2—renal system—uterine cancer	0.00018	0.00358	CbGeAlD
Methotrexate—ABCC10—female reproductive system—uterine cancer	0.000179	0.00357	CbGeAlD
Methotrexate—SLC16A1—female gonad—uterine cancer	0.000177	0.00354	CbGeAlD
Methotrexate—ABCC1—uterine cervix—uterine cancer	0.000169	0.00337	CbGeAlD
Methotrexate—AOX1—female gonad—uterine cancer	0.000167	0.00334	CbGeAlD
Methotrexate—AOX1—vagina—uterine cancer	0.000166	0.00332	CbGeAlD
Methotrexate—ABCC4—uterus—uterine cancer	0.000165	0.0033	CbGeAlD
Methotrexate—ABCC3—female gonad—uterine cancer	0.000164	0.00327	CbGeAlD
Methotrexate—ABCC10—female gonad—uterine cancer	0.000163	0.00325	CbGeAlD
Methotrexate—ABCC10—vagina—uterine cancer	0.000162	0.00323	CbGeAlD
Methotrexate—ABCC1—decidua—uterine cancer	0.000161	0.00321	CbGeAlD
Methotrexate—TYMS—Danazol—Progesterone—uterine cancer	0.000158	0.138	CbGdCrCtD
Methotrexate—SLCO1C1—lymph node—uterine cancer	0.000157	0.00314	CbGeAlD
Methotrexate—ABCC1—endometrium—uterine cancer	0.000153	0.00305	CbGeAlD
Methotrexate—ABCC4—female reproductive system—uterine cancer	0.000149	0.00296	CbGeAlD
Methotrexate—ABCC1—mammalian vulva—uterine cancer	0.000148	0.00295	CbGeAlD
Methotrexate—ABCC2—female reproductive system—uterine cancer	0.000144	0.00287	CbGeAlD
Methotrexate—ABCC1—uterus—uterine cancer	0.000141	0.00281	CbGeAlD
Methotrexate—MTHFR—lymph node—uterine cancer	0.000141	0.00281	CbGeAlD
Methotrexate—ABCG2—uterine cervix—uterine cancer	0.00014	0.00279	CbGeAlD
Methotrexate—SLCO3A1—lymph node—uterine cancer	0.000138	0.00276	CbGeAlD
Methotrexate—ABCC4—female gonad—uterine cancer	0.000135	0.0027	CbGeAlD
Methotrexate—ABCG2—decidua—uterine cancer	0.000133	0.00266	CbGeAlD
Methotrexate—TYMS—lymph node—uterine cancer	0.000128	0.00256	CbGeAlD
Methotrexate—DHFR—lymph node—uterine cancer	0.000127	0.00253	CbGeAlD
Methotrexate—ABCG2—endometrium—uterine cancer	0.000127	0.00252	CbGeAlD
Methotrexate—ABCG2—mammalian vulva—uterine cancer	0.000122	0.00244	CbGeAlD
Methotrexate—PGD—lymph node—uterine cancer	0.000122	0.00244	CbGeAlD
Methotrexate—ABCG2—uterus—uterine cancer	0.000117	0.00233	CbGeAlD
Methotrexate—ABCC1—female gonad—uterine cancer	0.000115	0.0023	CbGeAlD
Methotrexate—ABCC1—vagina—uterine cancer	0.000115	0.00228	CbGeAlD
Methotrexate—SLC16A1—lymph node—uterine cancer	0.000114	0.00227	CbGeAlD
Methotrexate—TYMS—Levonorgestrel—Progesterone—uterine cancer	0.000113	0.0989	CbGdCrCtD
Methotrexate—AOX1—lymph node—uterine cancer	0.000108	0.00215	CbGeAlD
Methotrexate—ABCC3—lymph node—uterine cancer	0.000105	0.0021	CbGeAlD
Methotrexate—ABCC10—lymph node—uterine cancer	0.000105	0.00209	CbGeAlD
Methotrexate—ABCG2—female gonad—uterine cancer	9.54e-05	0.0019	CbGeAlD
Methotrexate—ABCG2—vagina—uterine cancer	9.48e-05	0.00189	CbGeAlD
Methotrexate—ALB—lymph node—uterine cancer	8.98e-05	0.00179	CbGeAlD
Methotrexate—ABCB1—myometrium—uterine cancer	8.87e-05	0.00177	CbGeAlD
Methotrexate—ABCC4—lymph node—uterine cancer	8.69e-05	0.00173	CbGeAlD
Methotrexate—ABCC2—lymph node—uterine cancer	8.41e-05	0.00168	CbGeAlD
Methotrexate—ABCC1—lymph node—uterine cancer	7.41e-05	0.00148	CbGeAlD
Methotrexate—ABCB1—epithelium—uterine cancer	6.96e-05	0.00139	CbGeAlD
Methotrexate—ABCB1—uterine cervix—uterine cancer	6.9e-05	0.00138	CbGeAlD
Methotrexate—ABCB1—decidua—uterine cancer	6.57e-05	0.00131	CbGeAlD
Methotrexate—ABCB1—renal system—uterine cancer	6.46e-05	0.00129	CbGeAlD
Methotrexate—ABCB1—endometrium—uterine cancer	6.24e-05	0.00124	CbGeAlD
Methotrexate—ABCG2—lymph node—uterine cancer	6.13e-05	0.00122	CbGeAlD
Methotrexate—ABCB1—mammalian vulva—uterine cancer	6.04e-05	0.0012	CbGeAlD
Methotrexate—ABCB1—uterus—uterine cancer	5.75e-05	0.00115	CbGeAlD
Methotrexate—ABCB1—female reproductive system—uterine cancer	5.17e-05	0.00103	CbGeAlD
Methotrexate—Renal failure acute—Doxorubicin—uterine cancer	5.1e-05	0.000594	CcSEcCtD
Methotrexate—Osteoarthritis—Epirubicin—uterine cancer	5.09e-05	0.000593	CcSEcCtD
Methotrexate—Feeling abnormal—Dactinomycin—uterine cancer	5.08e-05	0.000592	CcSEcCtD
Methotrexate—Ill-defined disorder—Etoposide—uterine cancer	5.07e-05	0.000591	CcSEcCtD
Methotrexate—Anaemia—Etoposide—uterine cancer	5.05e-05	0.000589	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dactinomycin—uterine cancer	5.04e-05	0.000587	CcSEcCtD
Methotrexate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	5.03e-05	0.000585	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Doxorubicin—uterine cancer	4.99e-05	0.000581	CcSEcCtD
Methotrexate—Rash—Medroxyprogesterone Acetate—uterine cancer	4.98e-05	0.000581	CcSEcCtD
Methotrexate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	4.98e-05	0.00058	CcSEcCtD
Methotrexate—Headache—Medroxyprogesterone Acetate—uterine cancer	4.95e-05	0.000577	CcSEcCtD
Methotrexate—Malaise—Etoposide—uterine cancer	4.93e-05	0.000574	CcSEcCtD
Methotrexate—Vertigo—Etoposide—uterine cancer	4.91e-05	0.000572	CcSEcCtD
Methotrexate—Leukopenia—Etoposide—uterine cancer	4.89e-05	0.00057	CcSEcCtD
Methotrexate—Abdominal pain—Dactinomycin—uterine cancer	4.87e-05	0.000568	CcSEcCtD
Methotrexate—Body temperature increased—Dactinomycin—uterine cancer	4.87e-05	0.000568	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Doxorubicin—uterine cancer	4.87e-05	0.000567	CcSEcCtD
Methotrexate—Mood swings—Epirubicin—uterine cancer	4.82e-05	0.000562	CcSEcCtD
Methotrexate—Cerebrovascular accident—Doxorubicin—uterine cancer	4.81e-05	0.00056	CcSEcCtD
Methotrexate—Lethargy—Doxorubicin—uterine cancer	4.81e-05	0.00056	CcSEcCtD
Methotrexate—Ataxia—Epirubicin—uterine cancer	4.79e-05	0.000557	CcSEcCtD
Methotrexate—Cough—Etoposide—uterine cancer	4.77e-05	0.000556	CcSEcCtD
Methotrexate—Convulsion—Etoposide—uterine cancer	4.74e-05	0.000552	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—uterine cancer	4.71e-05	0.000549	CcSEcCtD
Methotrexate—ABCB1—female gonad—uterine cancer	4.7e-05	0.000938	CbGeAlD
Methotrexate—Liver function test abnormal—Epirubicin—uterine cancer	4.7e-05	0.000547	CcSEcCtD
Methotrexate—Nausea—Medroxyprogesterone Acetate—uterine cancer	4.7e-05	0.000547	CcSEcCtD
Methotrexate—ABCB1—vagina—uterine cancer	4.68e-05	0.000933	CbGeAlD
Methotrexate—Chest pain—Etoposide—uterine cancer	4.66e-05	0.000542	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	4.62e-05	0.000538	CcSEcCtD
Methotrexate—Discomfort—Etoposide—uterine cancer	4.6e-05	0.000536	CcSEcCtD
Methotrexate—Breast disorder—Epirubicin—uterine cancer	4.6e-05	0.000536	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Epirubicin—uterine cancer	4.58e-05	0.000534	CcSEcCtD
Methotrexate—Hypersensitivity—Dactinomycin—uterine cancer	4.54e-05	0.000529	CcSEcCtD
Methotrexate—Confusional state—Etoposide—uterine cancer	4.5e-05	0.000524	CcSEcCtD
Methotrexate—Anaphylactic shock—Etoposide—uterine cancer	4.46e-05	0.00052	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—uterine cancer	4.46e-05	0.00052	CcSEcCtD
Methotrexate—Infection—Etoposide—uterine cancer	4.43e-05	0.000516	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—uterine cancer	4.43e-05	0.000516	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—uterine cancer	4.42e-05	0.000515	CcSEcCtD
Methotrexate—Asthma—Epirubicin—uterine cancer	4.4e-05	0.000512	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—uterine cancer	4.37e-05	0.000509	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—uterine cancer	4.36e-05	0.000507	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—uterine cancer	4.35e-05	0.000506	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—uterine cancer	4.34e-05	0.000505	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—uterine cancer	4.31e-05	0.000502	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—uterine cancer	4.31e-05	0.000502	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—uterine cancer	4.26e-05	0.000496	CcSEcCtD
Methotrexate—Anorexia—Etoposide—uterine cancer	4.25e-05	0.000495	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	4.24e-05	0.000494	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—uterine cancer	4.22e-05	0.000491	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—uterine cancer	4.18e-05	0.000487	CcSEcCtD
Methotrexate—Hypotension—Etoposide—uterine cancer	4.17e-05	0.000486	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—uterine cancer	4.11e-05	0.000479	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—uterine cancer	4.11e-05	0.000479	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—uterine cancer	4.09e-05	0.000476	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—uterine cancer	4.07e-05	0.000474	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—uterine cancer	4.03e-05	0.000469	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—uterine cancer	4.02e-05	0.000468	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—uterine cancer	4.01e-05	0.000467	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—uterine cancer	3.99e-05	0.000465	CcSEcCtD
Methotrexate—Dyspnoea—Etoposide—uterine cancer	3.98e-05	0.000463	CcSEcCtD
Methotrexate—Somnolence—Etoposide—uterine cancer	3.97e-05	0.000462	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—uterine cancer	3.95e-05	0.000459	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—uterine cancer	3.92e-05	0.000457	CcSEcCtD
Methotrexate—Infestation—Epirubicin—uterine cancer	3.92e-05	0.000457	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—uterine cancer	3.92e-05	0.000457	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—uterine cancer	3.92e-05	0.000457	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—uterine cancer	3.89e-05	0.000453	CcSEcCtD
Methotrexate—Rash—Dactinomycin—uterine cancer	3.89e-05	0.000453	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—uterine cancer	3.88e-05	0.000452	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—uterine cancer	3.87e-05	0.00045	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—uterine cancer	3.86e-05	0.000449	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—uterine cancer	3.85e-05	0.000449	CcSEcCtD
Methotrexate—Fatigue—Etoposide—uterine cancer	3.85e-05	0.000448	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—uterine cancer	3.82e-05	0.000445	CcSEcCtD
Methotrexate—Pain—Etoposide—uterine cancer	3.82e-05	0.000444	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—uterine cancer	3.81e-05	0.000444	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—uterine cancer	3.81e-05	0.000443	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—uterine cancer	3.81e-05	0.000443	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—uterine cancer	3.78e-05	0.000441	CcSEcCtD
Methotrexate—Sweating—Epirubicin—uterine cancer	3.76e-05	0.000438	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—uterine cancer	3.74e-05	0.000436	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—uterine cancer	3.72e-05	0.000433	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—uterine cancer	3.71e-05	0.000432	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—uterine cancer	3.7e-05	0.000431	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—uterine cancer	3.68e-05	0.000428	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—uterine cancer	3.66e-05	0.000427	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—uterine cancer	3.66e-05	0.000426	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—uterine cancer	3.65e-05	0.000425	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—uterine cancer	3.65e-05	0.000425	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—uterine cancer	3.63e-05	0.000423	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—uterine cancer	3.63e-05	0.000423	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—uterine cancer	3.63e-05	0.000423	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	3.6e-05	0.000419	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—uterine cancer	3.57e-05	0.000416	CcSEcCtD
Methotrexate—Urticaria—Etoposide—uterine cancer	3.55e-05	0.000413	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—uterine cancer	3.54e-05	0.000412	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—uterine cancer	3.54e-05	0.000412	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—uterine cancer	3.53e-05	0.000411	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—uterine cancer	3.53e-05	0.000411	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—uterine cancer	3.53e-05	0.000411	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—uterine cancer	3.52e-05	0.00041	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—uterine cancer	3.52e-05	0.00041	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—uterine cancer	3.49e-05	0.000407	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—uterine cancer	3.48e-05	0.000405	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—uterine cancer	3.48e-05	0.000405	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—uterine cancer	3.46e-05	0.000403	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—uterine cancer	3.45e-05	0.000402	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—uterine cancer	3.43e-05	0.0004	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—uterine cancer	3.42e-05	0.000399	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—uterine cancer	3.39e-05	0.000395	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—uterine cancer	3.39e-05	0.000394	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—uterine cancer	3.33e-05	0.000388	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—uterine cancer	3.29e-05	0.000383	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—uterine cancer	3.29e-05	0.000383	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—uterine cancer	3.28e-05	0.000382	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—uterine cancer	3.27e-05	0.000381	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—uterine cancer	3.27e-05	0.000381	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—uterine cancer	3.26e-05	0.000379	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—uterine cancer	3.26e-05	0.000379	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—uterine cancer	3.23e-05	0.000377	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—uterine cancer	3.22e-05	0.000375	CcSEcCtD
Methotrexate—Asthenia—Etoposide—uterine cancer	3.2e-05	0.000373	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—uterine cancer	3.19e-05	0.000372	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—uterine cancer	3.19e-05	0.000372	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—uterine cancer	3.18e-05	0.00037	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—uterine cancer	3.17e-05	0.00037	CcSEcCtD
Methotrexate—Chills—Epirubicin—uterine cancer	3.16e-05	0.000368	CcSEcCtD
Methotrexate—Pruritus—Etoposide—uterine cancer	3.16e-05	0.000368	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—uterine cancer	3.14e-05	0.000366	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—uterine cancer	3.11e-05	0.000362	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—uterine cancer	3.08e-05	0.000359	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—uterine cancer	3.08e-05	0.000359	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—uterine cancer	3.07e-05	0.000357	CcSEcCtD
Methotrexate—Erythema—Epirubicin—uterine cancer	3.07e-05	0.000357	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—uterine cancer	3.05e-05	0.000356	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—uterine cancer	3.04e-05	0.000355	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—uterine cancer	3.04e-05	0.000354	CcSEcCtD
Methotrexate—ABCB1—lymph node—uterine cancer	3.02e-05	0.000603	CbGeAlD
Methotrexate—Cardiac disorder—Doxorubicin—uterine cancer	3.02e-05	0.000352	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—uterine cancer	3e-05	0.00035	CcSEcCtD
Methotrexate—Back pain—Epirubicin—uterine cancer	2.97e-05	0.000345	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—uterine cancer	2.96e-05	0.000344	CcSEcCtD
Methotrexate—Dizziness—Etoposide—uterine cancer	2.95e-05	0.000344	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—uterine cancer	2.94e-05	0.000343	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—uterine cancer	2.94e-05	0.000342	CcSEcCtD
Methotrexate—Chills—Doxorubicin—uterine cancer	2.92e-05	0.00034	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—uterine cancer	2.89e-05	0.000336	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—uterine cancer	2.88e-05	0.000335	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—uterine cancer	2.85e-05	0.000332	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—uterine cancer	2.84e-05	0.000331	CcSEcCtD
Methotrexate—Vomiting—Etoposide—uterine cancer	2.84e-05	0.00033	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—uterine cancer	2.84e-05	0.00033	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—uterine cancer	2.84e-05	0.00033	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—uterine cancer	2.83e-05	0.00033	CcSEcCtD
Methotrexate—Rash—Etoposide—uterine cancer	2.81e-05	0.000328	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—uterine cancer	2.81e-05	0.000327	CcSEcCtD
Methotrexate—Headache—Etoposide—uterine cancer	2.8e-05	0.000326	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—uterine cancer	2.78e-05	0.000323	CcSEcCtD
Methotrexate—Malaise—Epirubicin—uterine cancer	2.76e-05	0.000322	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—uterine cancer	2.75e-05	0.000321	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—uterine cancer	2.74e-05	0.00032	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—uterine cancer	2.74e-05	0.00032	CcSEcCtD
Methotrexate—Cough—Epirubicin—uterine cancer	2.67e-05	0.000312	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—uterine cancer	2.67e-05	0.000311	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—uterine cancer	2.66e-05	0.000309	CcSEcCtD
Methotrexate—Nausea—Etoposide—uterine cancer	2.65e-05	0.000309	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—uterine cancer	2.63e-05	0.000306	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—uterine cancer	2.62e-05	0.000305	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—uterine cancer	2.61e-05	0.000304	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—uterine cancer	2.61e-05	0.000304	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—uterine cancer	2.61e-05	0.000304	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	2.59e-05	0.000302	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—uterine cancer	2.58e-05	0.0003	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—uterine cancer	2.56e-05	0.000298	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—uterine cancer	2.55e-05	0.000297	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—uterine cancer	2.54e-05	0.000296	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—uterine cancer	2.52e-05	0.000294	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—uterine cancer	2.5e-05	0.000291	CcSEcCtD
Methotrexate—Infection—Epirubicin—uterine cancer	2.49e-05	0.000289	CcSEcCtD
Methotrexate—Cough—Doxorubicin—uterine cancer	2.48e-05	0.000288	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—uterine cancer	2.46e-05	0.000286	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—uterine cancer	2.45e-05	0.000286	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—uterine cancer	2.45e-05	0.000285	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—uterine cancer	2.43e-05	0.000283	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—uterine cancer	2.42e-05	0.000282	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—uterine cancer	2.41e-05	0.000281	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—uterine cancer	2.41e-05	0.000281	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—uterine cancer	2.41e-05	0.000281	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	2.4e-05	0.000279	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—uterine cancer	2.39e-05	0.000278	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—uterine cancer	2.38e-05	0.000278	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—uterine cancer	2.34e-05	0.000272	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—uterine cancer	2.33e-05	0.000272	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—uterine cancer	2.31e-05	0.00027	CcSEcCtD
Methotrexate—Infection—Doxorubicin—uterine cancer	2.3e-05	0.000268	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—uterine cancer	2.28e-05	0.000265	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—uterine cancer	2.27e-05	0.000264	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—uterine cancer	2.27e-05	0.000264	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—uterine cancer	2.26e-05	0.000264	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—uterine cancer	2.25e-05	0.000262	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—uterine cancer	2.25e-05	0.000262	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—uterine cancer	2.24e-05	0.000261	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—uterine cancer	2.23e-05	0.00026	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—uterine cancer	2.22e-05	0.000259	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—uterine cancer	2.21e-05	0.000257	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—uterine cancer	2.2e-05	0.000256	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—uterine cancer	2.17e-05	0.000253	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—uterine cancer	2.16e-05	0.000252	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—uterine cancer	2.16e-05	0.000252	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—uterine cancer	2.16e-05	0.000251	CcSEcCtD
Methotrexate—Pain—Epirubicin—uterine cancer	2.14e-05	0.000249	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	2.11e-05	0.000246	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—uterine cancer	2.09e-05	0.000244	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—uterine cancer	2.08e-05	0.000242	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—uterine cancer	2.06e-05	0.00024	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—uterine cancer	2.06e-05	0.00024	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—uterine cancer	2.06e-05	0.00024	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—uterine cancer	2.05e-05	0.000238	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—uterine cancer	2.04e-05	0.000237	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—uterine cancer	2.01e-05	0.000234	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—uterine cancer	2e-05	0.000233	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—uterine cancer	2e-05	0.000232	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—uterine cancer	1.99e-05	0.000231	CcSEcCtD
Methotrexate—Pain—Doxorubicin—uterine cancer	1.98e-05	0.000231	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—uterine cancer	1.98e-05	0.00023	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—uterine cancer	1.98e-05	0.00023	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—uterine cancer	1.91e-05	0.000222	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—uterine cancer	1.89e-05	0.00022	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—uterine cancer	1.84e-05	0.000215	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—uterine cancer	1.84e-05	0.000214	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—uterine cancer	1.83e-05	0.000213	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—uterine cancer	1.83e-05	0.000213	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—uterine cancer	1.79e-05	0.000209	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—uterine cancer	1.77e-05	0.000206	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—uterine cancer	1.71e-05	0.000199	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—uterine cancer	1.71e-05	0.000199	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—uterine cancer	1.66e-05	0.000193	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—uterine cancer	1.65e-05	0.000193	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—uterine cancer	1.64e-05	0.000191	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—uterine cancer	1.59e-05	0.000185	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—uterine cancer	1.58e-05	0.000184	CcSEcCtD
Methotrexate—Rash—Epirubicin—uterine cancer	1.58e-05	0.000184	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—uterine cancer	1.58e-05	0.000184	CcSEcCtD
Methotrexate—Headache—Epirubicin—uterine cancer	1.57e-05	0.000183	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—uterine cancer	1.53e-05	0.000178	CcSEcCtD
Methotrexate—Nausea—Epirubicin—uterine cancer	1.49e-05	0.000173	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—uterine cancer	1.47e-05	0.000171	CcSEcCtD
Methotrexate—Rash—Doxorubicin—uterine cancer	1.46e-05	0.00017	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—uterine cancer	1.46e-05	0.00017	CcSEcCtD
Methotrexate—Headache—Doxorubicin—uterine cancer	1.45e-05	0.000169	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—uterine cancer	1.37e-05	0.00016	CcSEcCtD
Methotrexate—ABCC1—Disease—AKR1C3—uterine cancer	8.38e-06	0.000197	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP11A1—uterine cancer	8.26e-06	0.000195	CbGpPWpGaD
Methotrexate—PGD—Disease—PTEN—uterine cancer	8.22e-06	0.000194	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—uterine cancer	8.19e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NDUFB11—uterine cancer	8.17e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SRD5A2—uterine cancer	8.17e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HMGA1—uterine cancer	8.17e-06	0.000192	CbGpPWpGaD
Methotrexate—FPGS—Disease—PIK3CA—uterine cancer	8.14e-06	0.000192	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—RRM2—uterine cancer	8.12e-06	0.000191	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NRAS—uterine cancer	8.09e-06	0.000191	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NRAS—uterine cancer	8.02e-06	0.000189	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKR1C1—uterine cancer	8.02e-06	0.000189	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PIK3CA—uterine cancer	8.02e-06	0.000189	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—MTHFR—uterine cancer	7.98e-06	0.000188	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—DCN—uterine cancer	7.89e-06	0.000186	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	7.88e-06	0.000186	CbGpPWpGaD
Methotrexate—PGD—Disease—EP300—uterine cancer	7.84e-06	0.000185	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—uterine cancer	7.82e-06	0.000184	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—EP300—uterine cancer	7.82e-06	0.000184	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKR1C3—uterine cancer	7.8e-06	0.000184	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—STK11—uterine cancer	7.73e-06	0.000182	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP19A1—uterine cancer	7.73e-06	0.000182	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—RRM2—uterine cancer	7.72e-06	0.000182	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—uterine cancer	7.56e-06	0.000178	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—uterine cancer	7.53e-06	0.000178	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTEN—uterine cancer	7.53e-06	0.000177	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—DCN—uterine cancer	7.49e-06	0.000177	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FBXW7—uterine cancer	7.47e-06	0.000176	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP11A1—uterine cancer	7.43e-06	0.000175	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—uterine cancer	7.34e-06	0.000173	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—MTHFR—uterine cancer	7.26e-06	0.000171	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.26e-06	0.000171	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—EP300—uterine cancer	7.18e-06	0.000169	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—RRM2—uterine cancer	7.15e-06	0.000168	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP11A1—uterine cancer	7.06e-06	0.000166	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKR1C3—uterine cancer	7.02e-06	0.000165	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—STK11—uterine cancer	6.98e-06	0.000164	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP19A1—uterine cancer	6.98e-06	0.000164	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—KRAS—uterine cancer	6.97e-06	0.000164	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—DCN—uterine cancer	6.94e-06	0.000164	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.92e-06	0.000163	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KRAS—uterine cancer	6.91e-06	0.000163	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTEN—uterine cancer	6.89e-06	0.000162	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	6.86e-06	0.000162	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PIK3CA—uterine cancer	6.82e-06	0.000161	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PIK3CA—uterine cancer	6.82e-06	0.000161	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STAR—uterine cancer	6.74e-06	0.000159	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1B1—uterine cancer	6.74e-06	0.000159	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKR1C3—uterine cancer	6.67e-06	0.000157	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	6.66e-06	0.000157	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—uterine cancer	6.65e-06	0.000157	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—MTHFR—uterine cancer	6.61e-06	0.000156	CbGpPWpGaD
Methotrexate—PGD—Metabolism—EP300—uterine cancer	6.57e-06	0.000155	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—uterine cancer	6.55e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.55e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP11A1—uterine cancer	6.54e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—EP300—uterine cancer	6.45e-06	0.000152	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—uterine cancer	6.41e-06	0.000151	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CA—uterine cancer	6.4e-06	0.000151	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB2—uterine cancer	6.36e-06	0.00015	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	6.35e-06	0.00015	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PIK3CA—uterine cancer	6.34e-06	0.00015	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—MTHFR—uterine cancer	6.33e-06	0.000149	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—uterine cancer	6.32e-06	0.000149	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.25e-06	0.000147	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB2—uterine cancer	6.22e-06	0.000146	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—uterine cancer	6.19e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKR1C3—uterine cancer	6.17e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—uterine cancer	6.11e-06	0.000144	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—STK11—uterine cancer	6.08e-06	0.000143	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP19A1—uterine cancer	6.08e-06	0.000143	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—uterine cancer	6.03e-06	0.000142	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	6e-06	0.000141	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—uterine cancer	5.92e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1B1—uterine cancer	5.91e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STAR—uterine cancer	5.91e-06	0.000139	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1B—uterine cancer	5.89e-06	0.000139	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—uterine cancer	5.87e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN2B—uterine cancer	5.85e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	5.85e-06	0.000138	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MTHFR—uterine cancer	5.81e-06	0.000137	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—uterine cancer	5.8e-06	0.000137	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1B—uterine cancer	5.76e-06	0.000136	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.7e-06	0.000134	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—uterine cancer	5.65e-06	0.000133	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—uterine cancer	5.6e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.58e-06	0.000131	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—uterine cancer	5.57e-06	0.000131	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—uterine cancer	5.57e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—uterine cancer	5.57e-06	0.000131	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP19A1—uterine cancer	5.47e-06	0.000129	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—STK11—uterine cancer	5.47e-06	0.000129	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.44e-06	0.000128	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—uterine cancer	5.44e-06	0.000128	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—uterine cancer	5.43e-06	0.000128	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—uterine cancer	5.37e-06	0.000127	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	5.36e-06	0.000126	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SMAD3—uterine cancer	5.34e-06	0.000126	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—uterine cancer	5.31e-06	0.000125	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—uterine cancer	5.3e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POLD1—uterine cancer	5.29e-06	0.000125	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	5.28e-06	0.000124	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTHFR—uterine cancer	5.24e-06	0.000124	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1B—uterine cancer	5.24e-06	0.000123	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—uterine cancer	5.23e-06	0.000123	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—STK11—uterine cancer	5.2e-06	0.000122	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP19A1—uterine cancer	5.2e-06	0.000122	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—uterine cancer	5.19e-06	0.000122	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—uterine cancer	5.18e-06	0.000122	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EP300—uterine cancer	5.17e-06	0.000122	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.13e-06	0.000121	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.12e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR2—uterine cancer	5.1e-06	0.00012	CbGpPWpGaD
Methotrexate—AOX1—Disease—EP300—uterine cancer	5.05e-06	0.000119	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1C1—uterine cancer	4.95e-06	0.000117	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—uterine cancer	4.95e-06	0.000117	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTHFR—uterine cancer	4.91e-06	0.000116	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.89e-06	0.000115	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.88e-06	0.000115	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—uterine cancer	4.86e-06	0.000115	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—uterine cancer	4.84e-06	0.000114	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—uterine cancer	4.82e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP19A1—uterine cancer	4.81e-06	0.000113	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—STK11—uterine cancer	4.81e-06	0.000113	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—uterine cancer	4.77e-06	0.000112	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—uterine cancer	4.74e-06	0.000112	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—uterine cancer	4.73e-06	0.000111	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.65e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POLD1—uterine cancer	4.64e-06	0.000109	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.62e-06	0.000109	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—uterine cancer	4.62e-06	0.000109	CbGpPWpGaD
Methotrexate—DHFR—Disease—EP300—uterine cancer	4.6e-06	0.000108	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—uterine cancer	4.57e-06	0.000108	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—uterine cancer	4.54e-06	0.000107	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.49e-06	0.000106	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—uterine cancer	4.44e-06	0.000105	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—uterine cancer	4.41e-06	0.000104	CbGpPWpGaD
Methotrexate—ALB—Metabolism—RRM2—uterine cancer	4.41e-06	0.000104	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—uterine cancer	4.34e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C1—uterine cancer	4.34e-06	0.000102	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—EP300—uterine cancer	4.33e-06	0.000102	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—uterine cancer	4.3e-06	0.000101	CbGpPWpGaD
Methotrexate—ALB—Metabolism—DCN—uterine cancer	4.28e-06	0.000101	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—uterine cancer	4.23e-06	9.98e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	4.19e-06	9.87e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—uterine cancer	4.17e-06	9.82e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	4.12e-06	9.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—uterine cancer	4.11e-06	9.68e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—uterine cancer	4.07e-06	9.59e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—uterine cancer	4.04e-06	9.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP11A1—uterine cancer	4.03e-06	9.51e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.02e-06	9.48e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.99e-06	9.4e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—uterine cancer	3.97e-06	9.36e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—uterine cancer	3.9e-06	9.2e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—uterine cancer	3.9e-06	9.19e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—RRM2—uterine cancer	3.86e-06	9.11e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—uterine cancer	3.85e-06	9.08e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—uterine cancer	3.83e-06	9.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1C3—uterine cancer	3.81e-06	8.98e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DCN—uterine cancer	3.75e-06	8.84e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—uterine cancer	3.74e-06	8.81e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—uterine cancer	3.7e-06	8.73e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—uterine cancer	3.68e-06	8.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.62e-06	8.53e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—uterine cancer	3.61e-06	8.52e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—uterine cancer	3.54e-06	8.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP11A1—uterine cancer	3.53e-06	8.33e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—uterine cancer	3.52e-06	8.3e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—uterine cancer	3.51e-06	8.27e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—uterine cancer	3.46e-06	8.15e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.44e-06	8.11e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	3.42e-06	8.06e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—uterine cancer	3.4e-06	8.02e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.37e-06	7.94e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—uterine cancer	3.36e-06	7.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C3—uterine cancer	3.34e-06	7.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—uterine cancer	3.23e-06	7.62e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—uterine cancer	3.21e-06	7.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—uterine cancer	3.2e-06	7.54e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—uterine cancer	3.15e-06	7.42e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—uterine cancer	3.13e-06	7.38e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—uterine cancer	3.13e-06	7.37e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—uterine cancer	3.08e-06	7.27e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—uterine cancer	3.05e-06	7.2e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STK11—uterine cancer	2.97e-06	7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—uterine cancer	2.97e-06	7e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—uterine cancer	2.96e-06	6.98e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—uterine cancer	2.92e-06	6.88e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—uterine cancer	2.92e-06	6.87e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—uterine cancer	2.85e-06	6.71e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—uterine cancer	2.8e-06	6.6e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.79e-06	6.57e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—uterine cancer	2.78e-06	6.56e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—uterine cancer	2.78e-06	6.55e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—uterine cancer	2.76e-06	6.52e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—uterine cancer	2.73e-06	6.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—uterine cancer	2.73e-06	6.43e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.66e-06	6.26e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—uterine cancer	2.62e-06	6.17e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—uterine cancer	2.6e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STK11—uterine cancer	2.6e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—uterine cancer	2.6e-06	6.13e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—uterine cancer	2.59e-06	6.12e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—uterine cancer	2.56e-06	6.03e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—uterine cancer	2.54e-06	5.99e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—uterine cancer	2.49e-06	5.86e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—uterine cancer	2.43e-06	5.74e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—uterine cancer	2.42e-06	5.71e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—uterine cancer	2.35e-06	5.54e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—uterine cancer	2.33e-06	5.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—uterine cancer	2.29e-06	5.39e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—uterine cancer	2.28e-06	5.37e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—uterine cancer	2.23e-06	5.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—uterine cancer	2.18e-06	5.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—uterine cancer	2.17e-06	5.12e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—uterine cancer	2.16e-06	5.09e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—uterine cancer	2.12e-06	5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—uterine cancer	2.1e-06	4.94e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—uterine cancer	2.09e-06	4.92e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—uterine cancer	2.07e-06	4.88e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—uterine cancer	2.06e-06	4.85e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—uterine cancer	2.03e-06	4.79e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—uterine cancer	2.01e-06	4.74e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—uterine cancer	2e-06	4.71e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.97e-06	4.63e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—uterine cancer	1.95e-06	4.61e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—uterine cancer	1.93e-06	4.54e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—uterine cancer	1.92e-06	4.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—uterine cancer	1.86e-06	4.39e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—uterine cancer	1.79e-06	4.22e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—uterine cancer	1.78e-06	4.2e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—uterine cancer	1.76e-06	4.16e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—uterine cancer	1.68e-06	3.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—uterine cancer	1.61e-06	3.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—uterine cancer	1.57e-06	3.71e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—uterine cancer	1.53e-06	3.61e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—uterine cancer	1.46e-06	3.45e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—uterine cancer	1.42e-06	3.34e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—uterine cancer	1.32e-06	3.1e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—uterine cancer	1.25e-06	2.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—uterine cancer	1.24e-06	2.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—uterine cancer	1.18e-06	2.79e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—uterine cancer	1.16e-06	2.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—uterine cancer	1.09e-06	2.56e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—uterine cancer	1.04e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—uterine cancer	8.75e-07	2.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—uterine cancer	7.67e-07	1.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—uterine cancer	7.15e-07	1.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—uterine cancer	6.27e-07	1.48e-05	CbGpPWpGaD
